Table 3.
Characteristics of the included studies involving patients with telogen effluvium.
| Author, year | Country | Study design | Group (case/control) | Mean age (SD) | Female (%) |
|---|---|---|---|---|---|
| Vandana et al. (2023) (84) | India | Descriptive | Patients with TE (76) | 24.40 (NR) | 76 (100) |
| Arslan et al. (2023) (96) | Turkey | Descriptive | Patients with TE (58†) | 27.54 (9.42) | 840 (86.3) |
| Chen et al. (2022) (24) | USA | Descriptive | Patients with pediatric TE (68†) | 12.3 (NR) | 67 (88) |
| deQueiroz et al. (2022) (27) | Brazil | Case–control | Patients with TE (17) | 42.8 (14.55) | 17 (100) |
| Unmatched controls with other skin conditions (33) | 38.8 (16.00) | 37 (100) | |||
| Oner and Akdeniz (2022) (31) | Turkey | Descriptive | Patients with TE (160) | 27.7 (8.8) | 156 (97.5) |
| Yorulmaz et al. (2022) (87) | Turkey | Descriptive | Patients with TE (1688†) | 26‡ (NR) | 2,794 (92.30) |
| Alizadeh et al. (2021) (88) | Iran | Case–control | Patients with TE (83) | 35‡ (NR) | 83 (100) |
| Age- and sex-matched healthy controls (83) | 35‡ (NR) | 83 (100) | |||
| Conic et al. (2021) (34) | USA | Descriptive | Patients with TE (121) | 46.9‡ (NR) | 120 (99.2) |
| Naser et al. (2021) (89) | Baghdad | Case–control | Patients with TE (60) | 32.6 (6.47) | 60 (100) |
| Age- and sex-matched healthy controls (60) | 41.3 (4.59) | 60 (100) | |||
| Mohammad et al. (2020) (90) | Iran | Case–control | Patients with TE (50) | NR | 50 (100) |
| Age- and sex-matched healthy controls who referred to dermatology clinic for cosmetic procedures other than hair loss (50) | NR | 50 (100) | |||
| Sokmen (2020) (91) | Turkey | Descriptive | Patients with TE (151) | 29‡ (NR) | 151 (100) |
| Conic et al. (2019) (37) | USA | Descriptive | Patients with TE (70) | 71.07 (5.35) | 68 (97.1) |
| Cifcia (2018) (92) | Turkey | Case–control | Patients with TE (155) | 30.7 (9.80) | 149 (96.13) |
| Age- and sex-matched healthy controls who visited other clinics for health checkup (168) | 30.76 (8.80) | 155 (92.26) | |||
| Sarac and Koca (2018) (78) | Turkey | Case–control | Patients with TE (71) | 26.6 (8.4) | 65 (91.55) |
| Unmatched healthy controls (58) | 28.5 (10.1) | 47 (81.03) | |||
| Gurel et al. (2017) (93) | Turkey | Case–control | Patients with TE (80) | 26.41 (6.93) | 80 (100) |
| Age- and sex-matched controls without hair loss (80) | 25.79 (7.41) | 80 (100) | |||
| Cheung et al. (2016) (94) | USA | Descriptive | Patients with TE (115†) | NR | 110 (26.63) |
| Rasheed et al. (2013) (81) | Egypt | Case–control | Patients with TE (42) | NR | 42 (100) |
| Age-, sex-, and FST- matched healthy female controls (40) | 30.8 (8.56) | 40 (100) | |||
| Karadag et al. (2011) (95) | Turkey | Case–control | Patients with TE (63) | 29.1 (11.9) | 63 (100) |
| Sex-matched controls without AA (50) | 28.4 (9.4) | 50 (100) |
FST, Fitzpatrick skin type; TE, telogen effluvium; USA, United States. † Number of patients with vitamin D results. ‡ Median age.